Progenity (PROG) has filed a prospectus for its IPO of ~6.7M common shares at $14 – 16 per share. Gross proceeds should be ~$100M (midpoint).
The molecular testing services provider’s lineup
consists of a non-invasive prenatal test for fetal chromosomal
disorders, an expanded carrier screen (preconception or early in
pregnancy) for genetic diseases, a hereditary cancer screen, a prenatal
test for monogenic disease and a portfolio of anatomic and molecular
pathology tests.
Selected competitors: LabCorp (NYSE:LH), Quest Diagnostics (NYSE:DGX), Natera (NASDAQ:NTRA), Myriad Genetics (NASDAQ:MYGN), Invitae (NYSE:NVTA)
https://seekingalpha.com/news/3582973-progenity-sets-ipo-terms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.